1
|
Zhang H, Li Q, Liao Y, Ma D, Zeng F, Zhang Z, Yu L, Yue R, Li X, Liao Y, Li D, Jang G, Zhao H, Zhao X, Zheng H, Li H, Liu L, Zhang Y. Immune Response Elicited by Recombinant Adenovirus-Delivered Glycoprotein B and Nucleocapsid Protein UL18 and UL25 of HSV-1 in Mice. Int J Mol Sci 2024; 25:13486. [PMID: 39769249 PMCID: PMC11678876 DOI: 10.3390/ijms252413486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Revised: 12/12/2024] [Accepted: 12/13/2024] [Indexed: 01/11/2025] Open
Abstract
Due to the complex pathogenic and immune escape mechanisms of herpes simplex virus type 1 (HSV-1), especially the failure of induced immune responses to block the initial cell-to-cell transmission of the virus from skin cells to neurons, the body struggles to establish effective prevention and control methods, resulting in the failure of currently developed vaccines. Previous studies have highlighted the crucial roles of surface glycoproteins and nucleocapsid proteins in activating the body's immune defense system against HSV-1 infection. In this study, recombinant adenoviruses were used as vectors to generate adenoviruses carrying the nucleocapsid protein genes UL18 and UL25, as well as the surface glycoprotein gene gB. This approach aimed to mimic the protein expression process that occurs following viral infection of the host and to investigate the immune response characteristics induced by UL18, UL25, and gB proteins. The findings revealed that UL18, UL25, and gB proteins could all trigger the expression of genes associated with innate immune responses; however, the specific genes induced varied in type and level. Furthermore, all three proteins were capable of promoting the proliferation of CD8+ T cells in the lymph nodes. Notably, only UL18 and gB could elicit a Th1 cell immune response. Interestingly, among these proteins, only UL18 could also induce a relatively higher IL-4 level, indicating a Th2 cell immune response. In addition to cellular immunity, all three proteins stimulated the production of specific IgG antibodies. Notably, UL18 induced higher and more sustained levels of specific IgG antibodies in mice. By contrast, only glycoprotein gB induced lower levels of neutralizing antibodies in mice. Moreover, when these mice were challenged with HSV-1, the co-immunization with UL18 and gB provided better protection than gB alone. In conclusion, HSV-1 surface glycoproteins and nucleocapsid proteins exhibit differences in their ability to induce innate and adaptive immunity in the body, suggesting potential avenues for vaccine design by leveraging their complementary advantages.
Collapse
Affiliation(s)
- Haobo Zhang
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
- School of Life Sciences, Yunnan University, Kunming 650500, China
| | - Qi Li
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
- School of Life Sciences, Yunnan University, Kunming 650500, China
| | - Yun Liao
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Danjing Ma
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Fengyuan Zeng
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
- School of Life Sciences, Yunnan University, Kunming 650500, China
| | - Zhenxiao Zhang
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Li Yu
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Rong Yue
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Xinghang Li
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Yuansheng Liao
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Dandan Li
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Guorun Jang
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Heng Zhao
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Xin Zhao
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Huiwen Zheng
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Heng Li
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Longding Liu
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| | - Ying Zhang
- Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College, Kunming 650118, China; (H.Z.); (Q.L.); (Y.L.); (D.M.); (F.Z.); (Z.Z.); (L.Y.); (R.Y.); (X.L.); (Y.L.); (D.L.); (G.J.); (H.Z.); (X.Z.); (H.Z.); (H.L.)
| |
Collapse
|
2
|
Sharma D, Farrar JD. Adrenergic regulation of immune cell function and inflammation. Semin Immunopathol 2020; 42:709-717. [PMID: 33219396 PMCID: PMC7678770 DOI: 10.1007/s00281-020-00829-6] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 11/14/2020] [Indexed: 02/06/2023]
Abstract
The sympathetic nervous system integrates the functions of multiple organ systems by regulating their autonomic physiological activities. The immune system is regulated both locally and systemically by the neurotransmitters epinephrine and norepinephrine secreted by the adrenal gland and local sympathetic neurons. Immune cells respond by activation of adrenergic receptors, primarily the β2-adrenergic receptor, which signal through heterotrimeric G-proteins. Depending upon the cell type, adrenergic signaling regulates a variety of functions in immune cells ranging from cellular migration to cytokine secretion. Furthermore, due to the diurnal oscillation of systemic norepinephrine levels, various immune functions follow a circadian rhythmic pattern. This review will highlight recent advances in our understanding of how the sympathetic nervous system regulates both innate and adaptive immune functions and how this regulation is linked to circadian rhythms.
Collapse
Affiliation(s)
- Drashya Sharma
- Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA
| | - J David Farrar
- Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA.
| |
Collapse
|
3
|
Bucsek MJ, Giridharan T, MacDonald CR, Hylander BL, Repasky EA. An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 2019; 34:135-143. [PMID: 29498310 DOI: 10.1080/02656736.2017.1411621] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Stress in patients and pre-clinical research animals plays a critical role in disease progression Activation of the sympathetic nervous system (SNS) by stress results in secretion of the catecholamines epinephrine (Epi) and norepinephrine (NE) from the adrenal gland and sympathetic nerve endings. Adrenergic receptors for catecholamines are present on immune cells and their activity is affected by stress and the accompanying changes in levels of these neurotransmitters. In this short review, we discuss how this adrenergic stress impacts two categories of immune responses, infections and autoimmune diseases. Catecholamines signal primarily through the β2-adrenergic receptors present on innate and adaptive immune cells which are critical in responding to infections caused by pathogens. In general, this adrenergic input, particularly chronic stimulation, suppresses lymphocytes and allows infections to progress. On the other hand, insufficient adrenergic control of immune responses allows progression of several autoimmune diseases.
Collapse
Affiliation(s)
- Mark J Bucsek
- a Department of Immunology , Roswell Park Cancer Institute , Buffalo , NY , USA
| | | | - Cameron R MacDonald
- a Department of Immunology , Roswell Park Cancer Institute , Buffalo , NY , USA
| | - Bonnie L Hylander
- a Department of Immunology , Roswell Park Cancer Institute , Buffalo , NY , USA
| | - Elizabeth A Repasky
- a Department of Immunology , Roswell Park Cancer Institute , Buffalo , NY , USA
| |
Collapse
|
4
|
Bacou E, Haurogné K, Mignot G, Allard M, De Beaurepaire L, Marchand J, Terenina E, Billon Y, Jacques J, Bach JM, Mormède P, Hervé J, Lieubeau B. Acute social stress-induced immunomodulation in pigs high and low responders to ACTH. Physiol Behav 2016; 169:1-8. [PMID: 27867043 DOI: 10.1016/j.physbeh.2016.11.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 11/07/2016] [Accepted: 11/08/2016] [Indexed: 01/11/2023]
Abstract
Pig husbandry is known as an intensive breeding system, piglets being submitted to multiple stressful events such as early weaning, successive mixing, crowding and shipping. These stressors are thought to impair immune defences and might contribute, at least partly, to the prophylactic use of antibiotics. Robustness was recently defined as the ability of an individual to express a high-production potential in a wide variety of environmental conditions. Increasing robustness thus appears as a valuable option to improve resilience to stressors and could be obtained by selecting piglets upon their adrenocortical activity. In this study, we aimed at depicting the consequences of an acute social stress on the immune capacity of piglets genetically selected upon divergent hypothalamic-pituitary-adrenocortical (HPA) axis activity. For this purpose, we monitored neuroendocrine and immune parameters, in high- (HPAhi) and low- (HPAlo) responders to ACTH, just before and immediately after a one-hour mixing with unfamiliar conspecifics. As expected, stressed piglets displayed higher levels of circulating cortisol and norepinephrine. Blood cell count analysis combined to flow cytometry revealed a stress-induced leukocyte mobilization in the bloodstream with a specific recruitment of CD8α+ lymphocytes. Besides, one-hour mixing decreased LPS-induced IL-8 and TNFα secretions in whole-blood assays (WBA) and reduced mononuclear cell phagocytosis. Altogether, our data demonstrate that acute social stress alters immune competence of piglets from both groups, and bring new insights in favour of good farming practices. While for most parameters high- and low-responders to ACTH behaved similarly, HPAhi piglets displayed higher number of CD4+ CD8α- T cells, as well as increased cytokine production in WBA (LPS-induced TNFα and PIL-induced IL-8), which could confer them increased resistance to pathogens. Finally, a principal component analysis including all parameters highlighted that overall stress effects were less pronounced on piglets with a strong HPA axis. Thus, selection upon adrenocortical axis activity seems to reduce the magnitude of response to stress and appears as a good tool to increase piglet robustness.
Collapse
Affiliation(s)
- Elodie Bacou
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Karine Haurogné
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Grégoire Mignot
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Marie Allard
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Laurence De Beaurepaire
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Jordan Marchand
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Elena Terenina
- GenPhySE, Université de Toulouse, INRA, INPT, ENVT, F-31326 Castanet-Tolosan, France
| | - Yvon Billon
- GenESI, INRA, Le Magneraud, F-17700 Saint-Pierre-d'Amilly, France
| | | | - Jean-Marie Bach
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France
| | - Pierre Mormède
- GenPhySE, Université de Toulouse, INRA, INPT, ENVT, F-31326 Castanet-Tolosan, France
| | - Julie Hervé
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France.
| | - Blandine Lieubeau
- IECM, INRA, Oniris, Université de Nantes, LUNAM, La Chantrerie, CS 40706, F-44307 Nantes Cedex 3, France.
| |
Collapse
|
5
|
Uyangaa E, Patil AM, Eo SK. Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus. Immune Netw 2014; 14:187-200. [PMID: 25177251 PMCID: PMC4148489 DOI: 10.4110/in.2014.14.4.187] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 07/28/2014] [Accepted: 08/04/2014] [Indexed: 12/01/2022] Open
Abstract
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are the most common cause of genital ulceration in humans worldwide. Typically, HSV-1 and 2 infections via mucosal route result in a lifelong latent infection after peripheral replication in mucosal tissues, thereby providing potential transmission to neighbor hosts in response to reactivation. To break the transmission cycle, immunoprophylactics and therapeutic strategies must be focused on prevention of infection or reduction of infectivity at mucosal sites. Currently, our understanding of the immune responses against mucosal infection of HSV remains intricate and involves a balance between innate signaling pathways and the adaptive immune responses. Numerous studies have demonstrated that HSV mucosal infection induces type I interferons (IFN) via recognition of Toll-like receptors (TLRs) and activates multiple immune cell populations, including NK cells, conventional dendritic cells (DCs), and plasmacytoid DCs. This innate immune response is required not only for the early control of viral replication at mucosal sites, but also for establishing adaptive immune responses against HSV antigens. Although the contribution of humoral immune response is controversial, CD4(+) Th1 T cells producing IFN-γ are believed to play an important role in eradicating virus from the hosts. In addition, the recent experimental successes of immunoprophylactic and therapeutic compounds that enhance resistance and/or reduce viral burden at mucosal sites have accumulated. This review focuses on attempts to modulate innate and adaptive immunity against HSV mucosal infection for the development of prophylactic and therapeutic strategies. Notably, cells involved in innate immune regulations appear to shape adaptive immune responses. Thus, we summarized the current evidence of various immune mediators in response to mucosal HSV infection, focusing on the importance of innate immune responses.
Collapse
Affiliation(s)
- Erdenebileg Uyangaa
- College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju 561-756, Korea
| | - Ajit Mahadev Patil
- College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju 561-756, Korea
| | - Seong Kug Eo
- College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju 561-756, Korea
| |
Collapse
|
6
|
Zhu XP, Muhammad ZS, Wang JG, Lin W, Guo SK, Zhang W. HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses 2014; 6:371-90. [PMID: 24469503 PMCID: PMC3939461 DOI: 10.3390/v6020371] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 01/16/2014] [Accepted: 01/17/2014] [Indexed: 01/08/2023] Open
Abstract
Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed. To facilitate this process, the latest progress in development of these vaccines is reviewed in this paper. A summary of the most promising HSV-2 vaccines tested in animals in the last five years is presented, including the main factors, and new ideas for developing an effective vaccine from animal experiments and human clinical trials. Experimental results indicate that future HSV-2 vaccines may depend on a strategy that targets mucosal immunity. Furthermore, estradiol, which increases the effectiveness of vaccines, may be considered as an adjuvant. Therefore, this review is expected to provide possible strategies for development of future HSV-2 vaccines.
Collapse
Affiliation(s)
- Xiao-Peng Zhu
- The 2nd Clinical Medical College, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| | - Zaka S Muhammad
- School of International Studies, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| | - Jian-Guang Wang
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| | - Wu Lin
- The 2nd Clinical Medical College, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| | - Shi-Kun Guo
- The 2nd Clinical Medical College, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| | - Wei Zhang
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou 325025, Zhejiang, China.
| |
Collapse
|
7
|
Cho A, Roh YS, Uyangaa E, Park S, Kim JW, Lim KH, Kwon J, Eo SK, Lim CW, Kim B. Protective effects of red ginseng extract against vaginal herpes simplex virus infection. J Ginseng Res 2013; 37:210-8. [PMID: 23717174 PMCID: PMC3659631 DOI: 10.5142/jgr.2013.37.210] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2012] [Revised: 11/07/2012] [Accepted: 11/07/2012] [Indexed: 11/18/2022] Open
Abstract
Numerous studies have suggested that Korean red ginseng (KRG) extract has various immune modulatory activities both in vivo and in vitro. In this study, we used a mouse model to examine the effects of orally administered KRG extract on immunity against herpes simplex virus (HSV). Balb/c mice were administered with 100, 200, and 400 mg/kg oral doses of KRG extract for 10 d and then vaginally infected with HSV. We found that KRG extract rendered recipients more resistant against HSV vaginal infection and further systemic infection, including decreased clinical severity, increased survival rate, and accelerated viral clearance. Such results appeared to be mediated by increased vaginal IFN-γ secretion. Moreover, increased mRNA expression of IFN-γ, granzyme B, and Fas-ligand was identified in the iliac lymph node and vaginal tracts of KRG extract treated groups (200 and 400 mg/kg). These results suggest that the activities of local natural killer cells were promoted by KRG extract consumption and that KRG may be an attractive immune stimulator for helping hosts overcome HSV infection.
Collapse
Affiliation(s)
- Ara Cho
- Biosafety Research Institute and College of Veterinary Medicine, Chonbuk National University, Jeonju 561-756, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ge G, Wang S, Han Y, Zhang C, Lu S, Huang Z. Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine. PLoS One 2012; 7:e41573. [PMID: 22844502 PMCID: PMC3402421 DOI: 10.1371/journal.pone.0041573] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Accepted: 06/24/2012] [Indexed: 12/19/2022] Open
Abstract
Although the use of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection, there are still a number of vaccine recipients who do not develop detectable antibody responses. Various novel vaccination approaches, including DNA vaccines, have been used to further improve the coverage of vaccine protection. Our previous studies demonstrated that HBsAg-based DNA vaccines could induce both humoral and CMI responses in experimental animal models. However, one form of the the HBsAg antigen, the large S antigen (HBs-L), expressed by DNA vaccine, was not sufficiently immunogenic in eliciting antibody responses. In the current study, we produced a modified large S antigen DNA vaccine, HBs-L(T), which has a truncated N-terminal sequence in the pre-S1 region. Compared to the original HBs-L DNA vaccine, the HBs-L(T) DNA vaccine improved secretion in cultured mammalian cells and generated significantly enhanced HBsAg-specific antibody and B cell responses. Furthermore, this improved HBsL DNA vaccine, along with other HBsAg-expressing DNA vaccines, was able to maintain predominantly Th1 type antibody responses while recombinant HBsAg protein vaccines produced in either yeast or CHO cells elicited mostly Th2 type antibody responses. Our data indicate that HBsAg DNA vaccines with improved immunogenicity offer a useful alternative choice to recombinant protein-based HBV vaccines, particularly for therapeutic purposes against chronic hepatitis infection where immune tolerance led to poor antibody responses to S antigens.
Collapse
Affiliation(s)
- Guohong Ge
- Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Shixia Wang
- China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Yaping Han
- Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Chunhua Zhang
- Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Shan Lu
- Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
- * E-mail:
| | - Zuhu Huang
- Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- China-US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
9
|
A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012; 86:6563-74. [PMID: 22491465 DOI: 10.1128/jvi.00302-12] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Genital herpes is caused by herpes simplex virus 1 (HSV-1) and HSV-2, and its incidence is constantly increasing in the human population. Regardless of the clinical manifestation, HSV-1 and HSV-2 infections are highly transmissible to sexual partners and enhance susceptibility to other sexually transmitted infections. An effective vaccine is not yet available. Here, HSV-1 glycoprotein B (gB1) was delivered by a feline immunodeficiency virus (FIV) vector and tested against HSV-1 and HSV-2 vaginal challenges in C57BL/6 mice. The gB1 vaccine elicited cross-neutralizing antibodies and cell-mediated responses that protected 100 and 75% animals from HSV-1- and HSV-2-associated severe disease, respectively. Two of the eight fully protected vaccinees underwent subclinical HSV-2 infection, as demonstrated by deep immunosuppression and other analyses. Finally, vaccination prevented death in 83% of the animals challenged with a HSV-2 dose that killed 78 and 100% naive and mock-vaccinated controls, respectively. Since this FIV vector can accommodate two or more HSV immunogens, this vaccine has ample potential for improvement and may become a candidate for the development of a truly effective vaccine against genital herpes.
Collapse
|
10
|
Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 2010; 29:1455-62. [PMID: 21185849 DOI: 10.1016/j.vaccine.2010.12.031] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 11/29/2010] [Accepted: 12/09/2010] [Indexed: 10/18/2022]
Abstract
Herpes stromal keratitis (HSK) is a chronic inflammatory process caused by the infection of herpes simplex virus type 1 (HSV-1). Development of a HSV-1 vaccine is a priority because these infections are common and cannot be well prevented. It appears that the potential of nanocarriers in DNA vaccination will be required to augment the immune response to DNA vaccines. Therefore, in the study, nanoparticles Fe(3)O(4) coated with glutamic acid, DNA vaccine pRSC-gD-IL-21 and polyethylenimine were prepared and immunized in the mice by ocular mucosal administration. The immune responses and protection efficiency against HSV-1 challenge were also tested. The results showed that the nanoparticles containing DNA vaccine pRSC-gD-IL-21 induced mice to generate higher levels of specific neutralizing antibody, sIgA in tears, and IFN-γ, IL-4 in serum, and to enhance the cytotoxicities of NK cells and splenocytes as well as splenocyte proliferative response to glycoprotein D compared with those of the control mice. More importantly, the mice immunized with the experimental vaccine showed less HSK degree than that of the control mice after HSV-1 challenge of the murine ocular mucosa. In conclusion, an ocular mucosal administration of nanoparticles containing DNA vaccine confers strong specific immune responses and effective inhibition of HSK in a HSV-1 infected murine model.
Collapse
Affiliation(s)
- Kai Hu
- Department of Pathogenic Biology and Immunology, Medical School, Southeast University, Nanjing 210009, China
| | | | | | | | | | | | | | | |
Collapse
|